卡爾維斯塔製藥公司
DE ˙ DB ˙ US4834971032
€23.01 0.00 (0.00%)
2026-06-04
分享價格
SecurityDE:4XC1 / KalVista Pharmaceuticals, Inc.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership2,242,025 shares
Ownership 6.50%
BlackRock, Inc. ownership in 4XC1 / KalVista Pharmaceuticals, Inc.

2024-01-29 - BlackRock, Inc. has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,242,025 shares of KalVista Pharmaceuticals, Inc. (DE:4XC1). This represents 6.5 percent ownership of the company. In their previous filing dated 2023-01-06 , BlackRock, Inc. had reported owning 1,572,421 shares, indicating an increase of 42.58 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-01-29 2024-01-29 13G 1,572,421 2,242,025 42.58 6.50 41.30
2023-01-06 2023-01-06 13G/A 1,504,620 1,572,421 4.51 4.60 -24.59
2022-02-01 2022-02-01 13G/A 1,113,380 1,504,620 35.14 6.10 -1.61
2021-02-02 2021-02-02 13G 1,113,380 6.20

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 3,795,897 41,749 1.11 76,411 26.03 0.0001
2026-02-12 2025-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 3,754,148 628,031 20.09 60,629 59.23 0.0010
2025-11-12 2025-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 3,126,117 -3,377 -0.11 38,076 7.63 0.0007
2025-08-12 2025-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 3,129,494 -22,241 -0.71 35,379 -2.73 0.0007
2025-05-02 2025-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 3,151,735 287,739 10.05 36,371 49.93 0.0008
2025-02-07 2024-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 2,863,996 -198,323 -6.48 24,258 -31.59 0.0005
2024-11-13 2024-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 3,062,319 117,203 3.98 35,462 2.21 0.0007
2024-08-13 2024-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 2,945,116 512,882 21.09 34,693 20.27 0.0008
2024-05-10 2024-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 2,432,234 190,209 8.48 28,846 5.03 0.0007
2024-02-13 2023-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 2,242,025 597,278 36.31 27,465 73.41 0.0007
2023-11-13 2023-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 1,644,747 45,009 2.81 15,839 10.01 0.0005
2023-08-11 2023-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 1,599,738 41,604 2.67 14,398 17.56 0.0004
2023-05-12 2023-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,558,134 -14,287 -0.91 12,247 15.21 0.0004
2023-02-13 2022-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,572,421 -133,727 -7.84 10,630 -57.07 0.0003
2022-11-14 2022-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 1,706,148 34,653 2.07 24,757 50.52 0.0008
2022-08-12 2022-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 1,671,495 127,468 8.26 16,448 -27.72 0.0005
2022-05-12 2022-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,544,027 39,407 2.62 22,757 14.32 0.0006
2022-02-10 2021-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,504,620 87,978 6.21 19,906 -19.47 0.0005
2021-11-09 2021-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 1,416,642 -9,780 -0.69 24,720 -27.67 0.0007
2021-08-11 2021-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 1,426,422 -133,066 -8.53 34,178 -14.69 0.0010
2021-05-07 2021-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,559,488 446,108 40.07 40,062 89.48 0.0012
2021-02-05 2020-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,113,380 198,646 21.72 21,143 83.58 0.0007
2020-11-06 2020-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 914,734 -9,117 -0.99 11,517 3.02 0.0004
2020-08-14 2020-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 923,851 51,394 5.89 11,179 67.50 0.0004
2020-05-01 2020-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 872,457 11,824 1.37 6,674 -56.46 0.0003
2020-02-13 2019-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 860,633 94,121 12.28 15,327 72.41 0.0006
2019-11-08 2019-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 766,512 29,730 4.04 8,890 -45.53 0.0004
2019-08-22 2019-06-30 13F/A-1 KALVISTA PHARMACEUTICALS COM 483497103 736,782 666,525 948.70 16,320 711.54 0.0007
2019-08-13 2019-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 736,782 666,525 16,320
2019-05-09 2019-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 70,257 25,179 55.86 2,011 125.70 0.0001
2019-02-08 2018-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 45,078 25,769 133.46 891 108.67 0.0000
2018-11-09 2018-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 19,309 3,104 19.15 427 223.48 0.0000
2018-08-09 2018-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 16,205 10,871 203.81 132 164.00 0.0000
2018-05-09 2018-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 5,334 368 7.41 50 2.04 0.0000
2018-02-09 2017-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 4,966 236 4.99 49 53.13 0.0000
2017-11-14 2017-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 4,730 399 9.21 32 0.00 0.0000
2017-08-10 2017-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 4,331 913 26.71 32 18.52 0.0000
2017-05-12 2017-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 3,418 3,418 27 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.